期刊文献+

PSAD在PSA 4~10ng患者前列腺癌诊断中的价值 被引量:13

Significance of prostate-specific antigen density for detecting prostate cancer in men with serum PSA levels of 4~10 ng
下载PDF
导出
摘要 目的探讨前列腺特异性抗原密度(PSAD)在前列腺特异性抗原(PSA)值介于4~10ng之间患者前列腺腺癌诊断中的应用价值。方法回顾性分析183例血清PSA值介于4~10ng之间疑似前列腺癌患者的临床资料,所有患者均经直肠B超测得前列腺体积后再行经直肠超声引导下前列腺穿刺术,通过接受者工作特征曲线分析法评价PSAD在预测诊断前列腺癌中的应用价值。结果 183例患者中36例经直肠超声下前列腺活检的患者被诊断为前列腺癌,占19.7%。良性前列腺增生组与前列腺癌患者之间,PSA(0.681 5)与PSAD(0.721 4)的曲线下方面积比较相似,而游离前列腺特异性抗原与总前列腺特异性抗原比值(f/tPSA)的曲线下面积只有0.318 2,相比PSA,PSAD值将是一个更好的预测前列腺癌的指标。结论 PSAD对于PSA值介于4~10ng/mL的中国患者是一项更好的预测前列腺癌的指标。 Objective To investigate the significance of prostate-specific antigen density(PSAD) for detecting prostate cancer in men with serum prostate specific antigen(PSA) levels of 4~10 ng/mL.Methods Data of 183 men with total PSA levels of 4-10 ng/mL who enrolled in a protocol for prostate cancer screening were analyzed.All patients were recommended for transrectal ultrasonography(TRUS) guided prostate biopsies after the prostate volumes were measured transrectally.Receiver operator characteristic(ROC) was used to analyze the diagnostic value of PSAD in predictor of prostate cancer.Results Prostate cancer was diagnosed in 36(19.7%) of the 183 men who had transrectal ultrasonography guided prostate biopsies.The area under the curve(AUC) of PSA(0.681 5) and PSAD(0.721 4) was similar and significantly greater than that of f/tPSA(0.318 2).PSAD was a better indicator of prostate cancer than f/t PSA.Conclusions PSAD is a better predictor of prostate cancer in Chinese men with PSA levels of 4~10 ng/mL.
出处 《现代泌尿外科杂志》 CAS 2012年第1期58-60,共3页 Journal of Modern Urology
关键词 前列腺特异性抗原(PSA) 前列腺特异性抗原密度(PSAD) 经直肠超声前列腺穿刺活检 前列腺癌 prostate specific antigen prostate-specific antigen density transrectal ultrasonography guided prostate biopsy prostate cancer
  • 相关文献

参考文献14

  • 1席志军,宁新荣,郝金瑞,那彦群,郭应禄.前列腺增生症PSA、PSAD与患者的年龄、前列腺体积的关系[J].中华外科杂志,2001,39(2):170-170. 被引量:14
  • 2PRESTI TC JR, CHANG JJ, BHARGAVA V,et al. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies:results of a prospective clinical trial [J]. J Urol, 2000, 163 (1):163-166.
  • 3JANI AB, JOHNSTONE PA, LIAUW SL, et al. Age and grade trends in prostate cancer (1974-2003), a surveillance, epidemiology and end results registry ananlysis [J]. Am J Clin Oncol, 2008, 31 (4):375-378.
  • 4YAMAMOTO S, MARUYAMA T, KONDOH N,et al.Diagnostic efficacy of free to total ratio of prostate-specific antigen and prostate-specific antigen velocity,singly and in combination,in detecting prostate cancer in patients with total serum prostate-specific antigen between 4 and 10 ng/mL[J].Int Urol Nephrol,2008,40(1):85-89.
  • 5STEPHAN C, JUNK K, LEIN M, et al. PSA and other tissue kallikreins for prostate cancer detection [J]. Eur J Cancer, 2007, 43 (13):1918-1926.
  • 6JEMAL A, SIEGEL R, WARD E, et al. Cancer statistics 2008[J]. CA Cancer J Clin,2008, 58:71-96.
  • 7ETZIONI R, TSODIKOV A, MARIOTTO A, et al. Quanifying the role of PSA screening in the US prostate cancer mortality decline[J]. Cancer Causes Cantrol, 2008, 19:175-181.
  • 8TOMIOKA S, SHIMBO M, AMIVA Y, et al. Significance of prostate-specific antigen-doubling time on survial of patients with hormone refractory prostate cancer and bone metastasis:analysis on 56 cases of cancer-specific death[J]. Int J Urol, 2007,14 (2):123-127.
  • 9LEE SE, CHUNG JS, HAN BK, et al. Relationship of prostate-specific antigen and prostate volume in Korean men with biopsy-proven benign prostatic hyperplasia[J]. Urology, 2008,71(3):395-398.
  • 10LOEB S, CATALONA WJ. Prostate-specific antigen in clinical practice[R]. Cancer Lett, 2007, 249 (1):30-39.

二级参考文献2

  • 1Seaman E,Urol Clin N Am,1993年,20卷,653页
  • 2Benson M C,J Urol,1992年,147卷,915页

共引文献13

同被引文献111

引证文献13

二级引证文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部